Back to Search
Start Over
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab:subgroup analysis of REGAIN and its extension study
- Source :
- Siddiqi, Z A, Nowak, R J, Mozaffar, T, O'Brien, F, Yountz, M, Patti, F, Mazia, C G, Wilken, M, Wilken, M, Barroso, F, Saba, J, Rugiero, M, Bettini, M, Chaves, M, Vidal, G, Garcia, A D, De Bleecker, J, Van den Abeele, G, de Koning, K, De Mey, K, Mercelis, R, Mahieu, D, Wagemaekers, L, Van Damme, P, Depreitere, A, Schotte, C, Smetcoren, C, Stevens, O, Van Daele, S, Vandenbussche, N, Vanhee, A, Verjans, S, Vynckier, J, D'Hont, A, Tilkin, P, de Siqueira Carvalho, A A, Brockhausen, I D, Feder, D, Ambrosio, D, César, P, Melo, A P, Ribeiro, R M, Rocha, R, Rosa, B B, Andersen, H, Vissing, J, Højgaard, J, Witting, N, Pedersen, J, Weiss, M & The REGAIN Study Group 2021, ' Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab : subgroup analysis of REGAIN and its extension study ', Muscle and Nerve, vol. 64, no. 6, pp. 662-669 . https://doi.org/10.1002/mus.27422, Muscle & nerve, 64(6), 662-669. John Wiley and Sons Inc.
- Publication Year :
- 2021
-
Abstract
- Introduction/Aims: Individuals with refractory generalized myasthenia gravis (gMG) who have a history of rituximab use and experience persistent symptoms represent a population with unmet treatment needs. The aim of this analysis was to evaluate the efficacy and safety of eculizumab in patients with refractory anti-acetylcholine receptor antibody-positive (AChR+) gMG previously treated with rituximab. Methods: This post hoc subgroup analysis of the phase 3 REGAIN study (NCT01997229) and its open-label extension (OLE; NCT02301624) compared baseline characteristics, safety, and response to eculizumab in participants who had previously received rituximab with those who had not. Rituximab use was not permitted within the 6 months before screening or during REGAIN/OLE. Results: Of 125 REGAIN participants, 14 had received rituximab previously (7 received placebo and 7 received eculizumab). In the previous-rituximab group, 57% had used at least four other immunosuppressants compared with 16% in the no-previous-rituximab group. Myasthenia Gravis Activities of Daily Living total scores from eculizumab baseline to week 130 of eculizumab treatment improved in both the previous-rituximab and no-previous-rituximab groups (least-squares mean −4.4, standard error of the mean [SEM] 1.0 [n = 9] and least-squares mean −4.6, SEM 0.3 [n = 67], respectively; difference = 0.2, 95% confidence interval −1.88 to 2.22). In addition, in both groups, most patients who were treated with eculizumab for 130 weeks achieved a Myasthenia Gravis Foundation of America post-intervention status of minimal manifestations (66.7% and 65.0%, respectively). The eculizumab safety profile was similar between groups and consistent with its established profile. Discussion: Eculizumab is an effective therapy for patients with refractory AChR+ gMG, irrespective of whether they had received rituximab treatment previously.
- Subjects :
- medicine.medical_specialty
Physiology
Population
Subgroup analysis
Antibodies, Monoclonal, Humanized
Placebo
Cellular and Molecular Neuroscience
rituximab
Refractory
immune system diseases
Physiology (medical)
Internal medicine
Activities of Daily Living
medicine
Humans
education
education.field_of_study
myasthenia gravis
acetylcholine receptor
business.industry
Eculizumab
medicine.disease
Confidence interval
Myasthenia gravis
refractory
Rituximab
eculizumab
Neurology (clinical)
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 0148639X
- Database :
- OpenAIRE
- Journal :
- Siddiqi, Z A, Nowak, R J, Mozaffar, T, O'Brien, F, Yountz, M, Patti, F, Mazia, C G, Wilken, M, Wilken, M, Barroso, F, Saba, J, Rugiero, M, Bettini, M, Chaves, M, Vidal, G, Garcia, A D, De Bleecker, J, Van den Abeele, G, de Koning, K, De Mey, K, Mercelis, R, Mahieu, D, Wagemaekers, L, Van Damme, P, Depreitere, A, Schotte, C, Smetcoren, C, Stevens, O, Van Daele, S, Vandenbussche, N, Vanhee, A, Verjans, S, Vynckier, J, D'Hont, A, Tilkin, P, de Siqueira Carvalho, A A, Brockhausen, I D, Feder, D, Ambrosio, D, César, P, Melo, A P, Ribeiro, R M, Rocha, R, Rosa, B B, Andersen, H, Vissing, J, Højgaard, J, Witting, N, Pedersen, J, Weiss, M & The REGAIN Study Group 2021, ' Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab : subgroup analysis of REGAIN and its extension study ', Muscle and Nerve, vol. 64, no. 6, pp. 662-669 . https://doi.org/10.1002/mus.27422, Muscle & nerve, 64(6), 662-669. John Wiley and Sons Inc.
- Accession number :
- edsair.doi.dedup.....3de965872b87e10335da1035c647c1c4